Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336) Stock Analysis

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a growth in Net Profit of 127.57%, the company declared Very Positive results in Mar 25

The company has declared positive results for the last 10 consecutive quarters
OPERATING CASH FLOW(Y) Highest at CNY 770.67 MM
ROCE(HY) Highest at 13.44%
RAW MATERIAL COST(Y) Fallen by -4.07% (YoY)

With ROE of 12.41%, it has a fair valuation with a 5.76 Price to Book Value

Market Beating performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 32,850 Million (Large Cap)

P/E

46.00

Industry P/E

Dividend Yield

0.23%

Debt Equity

-0.46

Return on Equity

12.41%

Price to Book

5.76

Revenue and Profits:

Net Sales:

329 Million

(Quarterly Results - Jun 2025)

Net Profit:

86 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

16.47%

6 Months

9.2%

1 Year

179.19%

2 Years

156.47%

3 Years

345.3%

4 Years

244.03%

5 Years

136.04%

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

3.98%

EBIT Growth (5y)

4.39%

EBIT to Interest (avg)

22.12

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.23

Sales to Capital Employed (avg)

0.21

Tax Ratio

4.65%

Dividend Payout Ratio

10.77%

Pledged Shares

Institutional Holding

ROCE (avg)

2.47%

ROE (avg)

3.89%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

5.76

EV to EBIT

142.65

EV to EBITDA

89.73

EV to Capital Employed

9.77

EV to Sales

24.60

PEG Ratio

Dividend Yield

0.23%

ROCE (Latest)

6.85%

ROE (Latest)

12.41%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.40% vs 22.22% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 140.45% vs -39.25% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "328.60",
          "val2": "327.30",
          "chgp": "0.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "63.80",
          "val2": "69.20",
          "chgp": "-7.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "13.40",
          "val2": "-0.30",
          "chgp": "4,566.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "85.60",
          "val2": "35.60",
          "chgp": "140.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "99.80%",
          "val2": "112.10%",
          "chgp": "-1.23%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 17.88% vs 22.63% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 143.97% vs 524.23% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,184.30",
          "val2": "1,004.70",
          "chgp": "17.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "334.50",
          "val2": "287.30",
          "chgp": "16.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.40",
          "val2": "1.60",
          "chgp": "-12.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "28.90",
          "val2": "19.40",
          "chgp": "48.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "691.40",
          "val2": "283.40",
          "chgp": "143.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "174.40%",
          "val2": "190.30%",
          "chgp": "-1.59%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

328.60

327.30

0.40%

Operating Profit (PBDIT) excl Other Income

63.80

69.20

-7.80%

Interest

0.30

Exceptional Items

13.40

-0.30

4,566.67%

Consolidate Net Profit

85.60

35.60

140.45%

Operating Profit Margin (Excl OI)

99.80%

112.10%

-1.23%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.40% vs 22.22% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 140.45% vs -39.25% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

1,184.30

1,004.70

17.88%

Operating Profit (PBDIT) excl Other Income

334.50

287.30

16.43%

Interest

1.40

1.60

-12.50%

Exceptional Items

28.90

19.40

48.97%

Consolidate Net Profit

691.40

283.40

143.97%

Operating Profit Margin (Excl OI)

174.40%

190.30%

-1.59%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 17.88% vs 22.63% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 143.97% vs 524.23% in Dec 2023

All Annual Results

Company CV

About Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available